drugset / Trial / NCT02194257

Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers

NCT02194257

Phase 1 Completed 12 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to determine the basic pharmacokinetics of ambroxol and \[14C\]-radioactivity including mass balance, excretion pathways and complete metabolism in healthy male volunteers following administration of a lozenge of 20 mg ambroxol together with an oral solution of 0.4 mg \[14C\]-ambroxol labelled in two different positions

Timeline

Start
2008-10
Primary completion
2008-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule 0.4 mg Oral
Subject Ambroxol Small molecule 20 mg Oral

Indications

No indication recorded.